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A B S T R A C T
Objective: Cisplatin is a chemotherapeutic drug known to induce hearing loss. Although corticosteroids may help
to mitigate the ototoxic side effects of cisplatin, there are complications associated with their systemic and
prolonged use. The goal of this study is to test the efficacy of extended-release fluticasone propionate intraco-
chlear implant particles to protect against cisplatin-induced hearing loss.
Methods: We used guinea pigs (n= 9) injected with cisplatin (IP, 12mg/kg weight). Fluticasone particles were
delivered to the cochlear scala tympani through the round window membrane into the right ears of the guinea
pigs (left ears being used as a control) two weeks prior to cisplatin administration, and hearing function was
evaluated by ABR and DPOAE before implantation, immediately before cisplatin administration, and 2 weeks
after the challenge with cisplatin. Data was statistically evaluated using paired t-test analysis.
Results: No significant differences were observed in ABR threshold between control and implanted ears on day
14 (23.9 ± 2.3 dB vs. 25.6 ± 1.3 dB, P= 0.524), whereas the significant cisplatin-induced hearing loss in
control animals (23.9 ± 2.3 dB at day 14 vs. 40.7 ± 2.5 dB at day 28, P≤ 0.0001) was prevented in implanted
animals (25.6 ± 1.3 dB at day 14 vs. 25.0 ± 3.1 at day 28, P≥ 0.85). A similar, though not statistically sig-
nificant, trend was observed in DPOAE responses in untreated ears (7.9 ± 5.8 dB at day14 vs.−0.5 ± 5.3 dB at
day 28, P= 0.654) as compared to treatment (11.1 ± 3.4 dB at day 14 vs. 13.6 ± 4.8 dB at day 28, P=0.733).
Conclusion: These results suggest that fluticasone intracochlear implants are safe and able to provide effective
otoprotection against cisplatin-induced hearing loss in the guinea pig model.
1. Introduction
Cisplatin is a potent anti-neoplastic agent frequently used in the
clinic for the treatment of a variety of solid tumors, such as ovarian,
testicular, cervical, lung, head, neck and bladder cancers. Its adminis-
tration, however, is commonly associated with severe nephrotoxicity,
peripheral neuropathy, and ototoxicity [1]. The Royal National In-
stitute for Deaf People's 2005 Ototoxicity and Otoprotective Agents
Market Report estimated that 700,000 new cancer patients in the
United States and Western Europe receive cisplatin chemotherapy each
year. This patient number increases to about 1 million when including
those receiving cisplatin for advanced or recurrent cancer.
Studies have shown that increasing doses of cisplatin are correlated
with increasing loss of outer hair cells (OHC), one of the two types of
auditory sensory cells together with inner hair cells (IHC), leading to
irreversible hearing loss [2–5]. This side effect of cisplatin is especially
pronounced in young children, with a tremendous impact on speech,
cognitive, and social development [6,7]. The symptoms associated with
ototoxicity in children may occur within hours after cisplatin admin-
istration; however, delayed ototoxicity can also occur years after [8].
Recent studies have shown that cisplatin is retained in the tissues of the
inner ear of mice and humans for much longer periods than was pre-
viously thought, with cisplatin detected months to years after the last
administration [9]. Currently, no regulatory approved drug-based
therapy for the prevention or treatment of cisplatin's ototoxic side ef-
fects is available. Based on the long-term retention of cisplatin in the
inner ear, any approved medication should either prevent passage of
cisplatin into the inner ear or have the capability to continually protect
against ototoxicity for months to years. In a previous study [10], we
described an extended-release fluticasone propionate particle formula-
tion, termed OR-102, developed for direct implantation into the co-
chlea. Moreover, we demonstrated that individual OR-102 particles can
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release fluticasone propionate inside the cochlear for up to six months,
and ears receiving the implanted particle exhibited no changes in
hearing function when compared to control ears [10].
The purpose of this study was to determine the in vivo efficacy of the
extended-release fluticasone propionate particle OR-102 for cisplatin-
induced hearing loss using a guinea pig model. This has the dual pur-
pose of demonstrating the retention of drug activity through manu-
facture and drug release in vivo as well as validating the protective
activity of fluticasone against cisplatin-dependent hearing loss.
2. Materials and methods
2.1. Animals
Young albino guinea pigs (Cavia porcellus, 200–300 g, n= 9) were
used for intracochlear implantation experiments, with all experimental
procedures approved by the House Ear Institute Institutional Animal
Care and Use Committee (approval number #HE1121-10-11).
2.2. Production of extended release fluticasone propionate particles
USP Fluticasone propionate was purchased from Molcan
Corporation, Ontario, Canada. The polymer used in this study is a
thermally modified polyvinyl alcohol to produce the final extended
release fluticasone propionate particle (OR-102) [10]. Particle batches
were size fractionated via sieving with a 180 μm sieve to enrich for the
desired size ranges. Batch release was performed using sieved particles.
Parameters for size/shape of particles and the correlation with drug
load were performed to establish criteria for particle selection. Fluti-
casone propionate particles 45–212 μm in size were selected for PVA
coating. PVA was cross-linked via heat treatment for a 100 + day re-
lease time-frame. Particles were run through a selection criteria in order
to obtain similar particles for each study. Particles were visualized
using light microscopy. Particle length and diameter were measured
with a graticule and accepted only if they fell within a specific range.
Accepted particles were cylindrical/hexagonal in shape. Drug crystal
integrity was examined to eliminate any particles with cracks along the
length and particle topography was assessed for the presence of smaller
attached particles, crystals or polymer masses. Any imperfections were
cause for rejection.
2.3. Scanning electron microscopy (SEM)
The surface topography of the OR-102 particles was investigated by
Scanning Electron Microscopy using an XL 30 S FEG operating at 5kVa
(FEI Inc, Hillsboro, OR). Analysis of the coated OR-102 particles’ sur-
face showed complete coating of the drug crystals. Moderate agglom-
eration of polymer was observed in some samples. Substantial ag-
glomeration of polymer can occlude the particle surface and impede
drug release. However, the level of occlusion was generally minimal.
Particle selection criteria mentioned above were developed to select
particles with little or no polymer agglomeration on the surface (Fig. 1).
2.4. In vivo implantation of extended release fluticasone particles
OR-102 particles were selected based on size, shape, and results of
topographical analysis via SEM imaging as described above. These
particles were used in these studies and implanted into the cochleae of
healthy albino guinea pigs prior to challenging the animals with cis-
platin (Fig. 2).
Guinea pigs received a single OR-102 implant particle through the
round window membrane into the scala tympani of their right ears,
with their left ears being used as a control. Under general anesthesia, a
postauricular incision was made over the bulla in the experimental ear.
A small hole was drilled through the bulla using a posterior approach
and small pieces of bone were chipped away until the RWM was clearly
visible and accessible (Fig. 3). Next, the ear was positioned with the
round window facing horizontally and superiorly, a 32-gauge needle
was used to puncture the round window, and the OR-102 particle was
placed in contact with the perilymph in the scala tympani. A drop of
sodium hyaluronate was placed over the round window injection site to
avoid leakage of perilymphatic fluids. A suture was used to close the
wound.
2.5. Cisplatin administration
Cisplatin was administered to guinea pigs via a single in-
traperitoneal injection, at a concentration of 12mg/kg, 14 days after
intracochlear implantation of OR-102.
2.6. Auditory measurements
Animals were anesthetized for auditory testing. Hearing was tested
Fig. 1. Scanning electron microscopy (SEM) of uncoated and coated (OR-102)
fluticasone propionate crystals.(a): SEM image of uncoated crystal. Particle was
examined by SEM using an XL 30 S FEG operating at 5kVa (FEI Inc, Hillsboro,
OR). (b): SEM image of OR-102. Coated particle was examined by SEM using an
XL 30 S FEG operating at 5kVa (FEI Inc, Hillsboro, OR). Moderate agglomera-
tion of the PVA polymer is evident on the surface of the crystal.
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pre-implant, 14, and 28 days post-implant. Auditory Brainstem
Responses (ABRs) were measured under computer control in response
to clicks 50 μs in duration from levels below threshold to 80 dB SPL in
5 dB steps. Responses were detected with subcutaneous needle elec-
trodes placed at the vertex and ventrolateral to the left and right pinna.
Response was amplified (10,000 times), filtered (0.1–3 kHz bandpass),
and averaged (across 512 sweeps at each frequency-level combination).
On visual inspection of stacked waveforms, “threshold” was defined as
the lowest stimulus level at which response peaks are present. These
visual detection threshold judgments were confirmed following termi-
nation of the experiment by offline display and analysis of the stored
waveforms.
DPOAE (2f1 – f2) Input/output functions were recorded. Response
amplitude was recorded as a function of L2 (L1 – L2= 10 dB); pri-
maries were incremented together in 5 dB steps (from 20 to 80 dB SPL)
spanning the frequency range f2= 5.6–45.2 kHz (f2/f1= 1.2). Ear-
canal sound pressures were amplified, digitally sampled, averaged until
a SNR of 6 dB is achieved. DPOAE level at 2f1 – f2 and surrounding
noise floor values (± 50Hz of 2f1 – f2) were extracted. DPOAE data
was compared with ABR data at corresponding frequencies. Responses
were recorded at baseline (before surgical exposure of the bulla), after
introduction of the particle, and prior to sacrifice.
2.7. Statistical analysis
Data was statistically analyzed via paired t tests utilizing GraphPad
QuickCalcs software (www.graphpad.com).
3. Results
Hearing assessments via auditory brainstem response (ABR) were
performed before implantation of OR-102 (pre-op day 1), pre-cisplatin
administration (14 days after implantation), and 14 days after cisplatin
administration (28 days after implantation). ABR results
(mean ± SEM) are depicted in Fig. 4. No significant differences were
observed in ABR threshold between control (non-implanted) and OR-
102 implanted ears on day 14 (compare pre-cisplatin day 14, No Sur-
gery and Implant ABR values: 23.9 ± 2.3 dB vs. 25.6 ± 1.3 dB,
P=0.524). However, a small but significant elevation in ABR threshold
was observed in implant ears between pre-op day 1, and pre-cisplatin
day 14 (compare OR-102 implant ears pre-op day 1 and pre-cisplatin
day 14: 19.4 ± 1.3 dB vs. 25.6 ± 1.3 dB, P=0.0158). This small
elevation in ABR threshold may be due to the surgical intervention. No
statistically significant differences were observed in ABR threshold in
control ears between pre-op day 1, and pre-cisplatin day 14 (compare
control ears pre-op day 1 and pre-cisplatin day 14: 22.8 ± 1.2 dB vs.
23.9 ± 2.3 dB, P=0.695).
In contrast, statistically significant hearing loss was observed in the
control ears following cisplatin treatment (compare pre-cisplatin day
14, and post-cisplatin day 28: 23.9 ± 2.3 dB vs. 40.7 ± 2.5 dB,
P≤ 0.0001). Importantly, no significant differences were observed in
ABR threshold between ears implanted with OR-102 when comparing
pre-cisplatin day 14, and post-cisplatin administration (compare day
28: 25.6 ± 1.3 dB vs. 25.0 ± 3.1 dB, P≥ 0.85). These results suggest
that OR-102 particles prevent cisplatin-induced hearing loss (Fig. 4).
Distortion product otoacoustic emissions (DPOAE) were also mon-
itored in all conditions tested (Fig. 5). In most circumstances, there was
no statistically significant difference in DPOAE measurements. This
may be due to the small sample size and/or large variability in readings
from the DPOAE testing method. However, there is an apparent trend
observed suggesting that cisplatin impairs hearing and that the im-
plantation of OR-102 extended release fluticasone particles. Specific
results are as follows. There was no statistically significant difference
between control and implant groups between pre-cisplatin day 14, and
post-cisplatin day 28 (control ears: compare pre-cisplatin day 14, and
post-cisplatin day 28: 7.9 ± 5.8 dB vs.−0.5 ± 5.3 dB, P= 0.654; OR-
102 treatment: compare pre-cisplatin day 14, and post-cisplatin day 28:
11.1 ± 3.4 dB vs. 13.6 ± 4.8 dB, P=0.733). There was also no sta-
tistically significant difference between control and implant ears at
post-cisplatin day 28 (compare control and implant ears, post-cisplatin
day 28: 0.5 ± 5.3 vs 13.6 ± 4.8, P= 0.120). Additionally, there was
no statistically significant difference in the OR-102 implant ear between
pre-surgery day 1, and pre-cisplatin day 14 (compare implant ears, pre-
op day 1, and pre-cisplatin day 14: 14.5 ± 4.5 vs 11.1 ± 3.4,
P= 0.572). However, a statistically significant difference was observed
in control ears between day 1 and day 14 (compare control ears, pre-op
day 1, and pre-cisplatin day 14: 15.0 ± 4.6 vs 7.9 ± 5.8, P=0.018).
4. Discussion
Our results suggest the efficacy of fluticasone propionate implants
delivered directly into the cochlea in the prevention of cisplatin-
Fig. 2. Study design: Animals were allowed to ac-
climate for a week prior to OR-102 implantation. At
14 days after implantation cisplatin was adminis-
tered via intraperitoneal (IP) injection. Hearing was
assessed a final time 14 days following cisplatin ad-
ministration and immediately before euthanasia. One
animal died shortly after cisplatin administration.
Another animal experienced extreme weight loss
after cisplatin administration and was euthanized.
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dependent hearing loss for over a course of four weeks.
4.1. Cisplatin and ototoxicity
Cisplatin is the chemotherapeutic agent of choice for the treatment
of a variety of solid tumors because of its ability to interfere with DNA
replication in cancerous cells. Cisplatin is commonly used for the
treatment of medulloblastoma, neuroblastoma, osteosarcoma, testi-
cular, ovarian, cervical, bladder, lung, and head and neck cancers [11].
However, cisplatin also interferes with DNA replication in healthy cells,
and it can induce cell death by different mechanisms even in non-di-
viding cells, such as OHCs and IHCs.
Cisplatin ototoxicity is characterized by progressive, bilateral and
irreversible hearing loss, preferentially affecting high frequencies [12].
Cisplatin affects mainly OHCs, although IHCs, spiral ganglion neurons
and stria vascularis cells are also major targets, by generating ROS and
activating inflammatory cytokines and stress signaling pathways
[13,14]. These events eventually lead to cell death, mostly via induc-
tion of apoptosis [13]. The loss of OHCs from systemic administration
of cisplatin correlates directly with the severity of hearing loss and is
thought to be the cause of cisplatin-dependent damage to hearing.
Young children are especially vulnerable to this ototoxic side effect of
cisplatin. As recent studies demonstrated, cisplatin is retained in the
tissue of the inner ear for weeks to months following administration
[9]. There are currently no approved medications for cisplatin's oto-
toxic side effects and any newly developed otoprotectant would need to
be present for the full duration of cisplatin's residency in the inner ear.
The development of an otoprotective treatment would have significant
impacts on patient quality of life.
4.2. Prevention of cisplatin-based hearing loss
Various compounds have been investigated as potential protective
agents against the side effects of cisplatin chemotherapy, including
antioxidants [15,16], neurotrophins [17,18], sulfur-containing nucleo-
philes [19], and corticosteroids [20,21]; other oral formulations are
currently in clinical trials. However, there is the risk that the high levels
of systemic drug required for otoprotection may decrease the effec-
tiveness of the cisplatin chemotherapy at its intended target. As such,
different strategies for delivery of otoprotective agents have been at-
tempted. One technique is intratympanic injections to locally admin-
ister the protective agent [20–23]. Other techniques include timing the
administration of systemic dosing of the protective agent such that it
does not disrupt chemotherapy function but retains otoprotective ac-
tivity [24]. The efficacy of these treatment options continues to be
tested in preclinical and clinical settings.
4.3. Extended release fluticasone formulation
Systemic administration of drug requires the agent to cross the
blood labyrinth barrier (BLB) to reach the inner ear [25,26]. However,
because only a small amount of drug is able to cross the BLB, high doses
of medication must be administered to achieve the appropriate drug
concentration and to have a therapeutic effect in the cochlea. Fur-
thermore, there are numerous negative side effects associated with the
systemic administration of drugs such as corticosteroids. Although the
intratympanic administration of pharmacological agents has been used
widely over the past few decades for the treatment of middle ear in-
dications [27–32], the drug must be retained in the middle ear cavity
and in contact with the round window membrane or the annular liga-
ment of the oval window for a sufficient amount of time in order to
deliver drug to the cochlea [28,33]. Yet, drugs administered to the
middle ear cavity have been shown to quickly discharge into the Eu-
stachian tube via mucociliary flow [34,35]. Increasing the frequency of
drug administration to compensate for this issue increases the cost of
therapy, the risk of tympanic membrane perforations [36], and the risk
of infection during the procedure [27]. Therefore, intracochlear drug
delivery systems have been developed to allow for improved dosing
control and reduced drug concentration gradients [37–40].
Corticosteroids remain attractive candidates for treating various
inner ear indications, including cisplatin-dependent hearing loss, as
they have been studied extensively and are well-characterized. With
their anti-inflammatory, vasodilating, and immunosuppressive effects,
corticosteroids are commonly used for the management of inner ear
disorders such as Meniere's disease, autoimmune inner ear disease, and
certain vestibular conditions. The published literature suggests that the
major advantage of topical steroid administration is in their ability to
achieve high local drug levels without the high systemic levels that
cause side effects [41].
Oral corticosteroids are not used clinically to prevent ototoxicity
due to the high dosage required and the complications associated with
their long-term use. Furthermore, it is possible that systemic
Fig. 3. Surgical procedure. (a): Round window in the horizontal plane in the
experimental ear. This was achieved by drilling a small hole through the bulla
using a posterior approach.(b): OR-102 implant sitting on round window. A 32-
gauge needle was used to puncture the round window and the OR-102 implant
was placed in the scala tympani.(c): Round window after insertion of OR-102.
After placement of OR-102 into the round window of the experimental ear, a
drop of sodium hyaluronate was placed over the round window injection site to
avoid leakage of perilymphatic fluids.
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corticosteroids could decrease the anti-cancer activity of cisplatin. A
study by Herr et al. has shown that systemic administration of dex-
amethasone, another corticosteroid, downregulates apoptotic genes in
carcinogenic cells [42]. Therefore, the local administration of corti-
costeroids can greatly enhance the efficacy of the drug as well as sig-
nificantly decrease the side effects of systemic corticosteroid adminis-
tration. Intratympanic injections of therapeutics can enhance uptake of
drugs into the inner ear while decreasing systemic exposure. However,
variabilities of the anatomy of the inner ear can make accurate dosing
difficult from patient to patient. The development of a corticosteroid
drug delivery system for intracochlear implantation can overcome these
limitations of systemic and intratympanic corticosteroid administra-
tion.
Devices such as the Norplant® [43] and the Vitrasert® [44] are
membrane-based drug delivery platforms that can permit linear/
pseudo-zero order drug delivery over a period of months. The Vitrasert®
implant is usually placed into the eye with a single implantation. This
membrane-based approach has additionally allowed researchers to
deliver corticosteroids to the eyes of animals for up to three years from
a single implantation [45] and is currently FDA approved for patients
with chronic noninfectious uveitis [46]. Thus, patients can constantly
be treated for symptoms for three years with a single implantation
event.
Previously, our group demonstrated the pharmacokinetics and
safety of an extended-release fluticasone propionate particle formula-
tion implanted directly into the cochlea of an animal model, demon-
strating drug release for up to a six-month time period [10]. In the
present study, we utilized the extended-release fluticasone particles to
mitigate the ototoxicity caused by cisplatin in a guinea pig model. The
results of this study demonstrate the release of active drug over a course
of at least four weeks as measured by protection against cisplatin-based
ototoxicity for at least four weeks after implantation. A major ad-
vantage of the extended-release drug delivery technology investigated
here is that it reduces or eliminates the burst release of drug and can
maintain steady drug release over the duration of months or years.
Previous studies with these extended-release fluticasone particles have
demonstrated release profiles for at least three months. Thus, a single
procedure to implant an intracochlear extended-release fluticasone
propionate particle could protect against cisplatin-based ototoxicity for
at least three months.
4.4. OR-102 protection against cisplatin ototoxicity
The OR-102 extended release fluticasone particles were tested for
their ability to protect against cisplatin-dependent ototoxicity. Auditory
brainstem response (ABR) results show that when animals are chal-
lenged with cisplatin, ears implanted with OR-102 exhibit statistically
significantly better hearing when compared to control ears. This sug-
gests the efficacy of OR-102 in the prevention of cisplatin-dependent
hearing loss. A slight, but statistically significant elevation in ABR
threshold is observed in implanted ears between day 1 (pre-implanta-
tion) and day 14 (pre-cisplatin). This may be due to the surgical pro-
cedure. However, as reported previously by our group, the surgical
technique and implantation of OR-102 particles can be performed with
little or no damage to hearing. Distortion product otoacoustic emissions
(DPOAE) were also measured and an apparent trend corroborating ABR
data results is observed. However, this apparent trend in DPOAE results
was not considered statistically significant. The lack of statistical
Fig. 4. Auditory brainstem response (ABR) thresh-
olds. Data shows no statistically significant hearing
loss between control ears and implanted ears at day
14 based on corresponding ABR thresholds. No sur-
gery (C) and Implant (I) ABR values (Mean ± SEM)
are as follows: Pre-Op: 22.8 ± 1.9 (C),
19.4 ± 1.3(I); 14 day: 23.9 ± 2.3 (C), 25.6 ± 1.3
(I); 28 day: 40.7 ± 2.5 (C), 25.0 ± 3.1 (I).
Statistically significant hearing loss was seen in
Control ears (No Surgery) following cisplatin treat-
ment between day 14 and day 28: 23.9 ± 2.3 dB vs.
40.7 ± 2.5 dB; P≤ 0.0001, demonstrating cisplatin
dependent hearing loss. There was no statistically
significant difference in ABR threshold between sur-
gery ears (Implant) between day 14 and day 28:
25.6 ± 1.3 dB vs. 25.0 ± 3.1 dB, P≥ 0.85, de-
monstrating otoprotection from OR-102. Stars in-
dicate statistical significance.
Fig. 5. Distortion product otoacoustic emissions
(DPOAEs). No Surgery (C) and Implant (I) DPOAE
values (Mean ± SEM) are as follows: Pre-Op:
15.0 ± 4.6 (C), 14.5 ± 4.5 (I); 14 day: 7.9 ± 5.8
(C), 11.1 ± 3.4 (I); 28 day: 0.5 ± 5.3 (C),
13.6 ± 4.8 (I). Data demonstrates prevention of
cisplatin dependent hearing loss from OR-102
Implant ears 14 days after cisplatin administration
(Day 28). DPOAE responses were absent in Control
ears 14 days after cisplatin administration but near
normal in Implant ears.
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significance may be due to the high level of variability in DPOAE results
and/or the small sample size. Additional animals would need to be
tested to determine if DPOAE results may actually corroborate ABR
results.
The OR-102 particles used in these studies are comprised of a solid
drug core encapsulated by a thin layer of polyvinyl alcohol (PVA)
polymer to control the release of the encapsulated drug. PVA is a syn-
thetic polymer derived from polyvinyl acetate and is known for its
biocompatibility and chemical resistance [47]. With its extensive safety
profile over the decades, PVA has proven to be a reliable polymer in
medical devices and as a coating agent for pharmaceutical agents
without affecting the device or drug being delivered through it [47–49].
It is unlikely that the PVA component of the OR-102 particle has any
effect on cisplatin or cisplatin-mediated ototoxicity. Each OR-102 pellet
contains ∼300 pg of cross-linked PVA which is biostable and is not
expected to break down over a 4-week period. This small amount of
material would have limited access and interaction with cisplatin in the
inner ear. Additionally, multiple PVA-based cisplatin drug delivery
systems have been developed that use PVA as a polymer in their shells
or hydrogels [50–55]. These extended-release cisplatin systems have
demonstrated that the use of PVA as a component did not sequester the
chemotherapeutic effects of cisplatin, and instead, showed that the PVA
controlled the release of cisplatin in vivo [50,51]. These previous studies
using PVA-based cisplatin drug delivery systems suggest that the PVA in
OR-102 would not sequester the chemotherapeutic properties of cis-
platin in vivo.
The use of experimental placebos is particularly indicated to in-
vestigate whether a given pharmacological drug is effective, per se, or if
its apparent beneficial effect is linked to a psychological and/or other
unknown mechanism/s. Corticosteroids like fluticasone, however, have
been extensively investigated, and there are no doubts about their ef-
ficacy in preventing cisplatin-induced hearing loss. As mentioned
above, one major problem with using corticosteroids is the well de-
scribed side effects associated with systemic approaches. This is the
issue that we try to tackle with our therapeutic approach using in-
tracochlear delivery of the drugs.
In our previous work [10] we described the pharmacokinetics of the
fluticasone released by the OR-102 intracochlear implant. Since the
goal of the present study is to demonstrate that the fluticasone released
by the implant is still effective in preventing cisplatin-induced hearing
loss and not to investigate whether the implant itself may contribute to
this effect, we saw no reason to use placebos.
5. Conclusion
Corticosteroids, such as fluticasone propionate, have been used
extensively for a variety of inner ear disorders. In this study, our group
has developed an extended-release fluticasone propionate particle for-
mulation (OR-102) to mitigate cisplatin-induced hearing loss. The local
administration of drug into the inner ear can reduce the potential for
systemic side effects of steroid administration while eliminating the
possibility of disrupting cisplatin activity against carcinogenic cells in
the rest of the body. The addition of OR-102 was shown to protect
against cisplatin-induced hearing loss over a course of four weeks. ABR
threshold results show no significant difference in OR-102 treated ears
following cisplatin treatment while untreated ears demonstrated sig-
nificant cisplatin-dependent hearing loss. These results suggest im-
plantation of extended-release steroid particles (OR-102) in the cochlea
protects from cisplatin-induced hearing damage in a guinea pig model
in a safely manner. Additional safety studies may be required on the
particles and surgical technique before clinical potential can be fully
ascertained. In addition to cisplatin-dependent hearing loss, the po-
tential exists to utilize OR-102 to treat a variety of inner ear disorders
that are responsive to long-term steroid treatment (i.e. autoimmune
inner ear disease). Although intracochlear implantation is more in-
vasive than intratympanic injection, we believe that procedures can be
developed to safely and reproducibly implant particles into the cochlea
with little risk of hearing damage or infection.
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